CR20140549A - Formas cristalinas de un modulador del receptor androgénico - Google Patents
Formas cristalinas de un modulador del receptor androgénicoInfo
- Publication number
- CR20140549A CR20140549A CR20140549A CR20140549A CR20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A
- Authority
- CR
- Costa Rica
- Prior art keywords
- androgenic
- crystal forms
- receiver modulator
- modulator
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente descripción se describe formas amorfas y cristalinas del modulador del receptor androgénico 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656888P | 2012-06-07 | 2012-06-07 | |
| PCT/US2013/044116 WO2013184681A1 (en) | 2012-06-07 | 2013-06-04 | Crystalline forms of an androgen receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140549A true CR20140549A (es) | 2015-04-06 |
Family
ID=49712550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190331A CR20190331A (es) | 2012-06-07 | 2013-06-04 | UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) |
| CR20140549A CR20140549A (es) | 2012-06-07 | 2014-12-01 | Formas cristalinas de un modulador del receptor androgénico |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190331A CR20190331A (es) | 2012-06-07 | 2013-06-04 | UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) |
Country Status (42)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2385960B1 (en) | 2009-01-12 | 2020-03-11 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
| CA2857061A1 (en) | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
| EP2858985B1 (en) | 2012-06-07 | 2018-04-18 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| RS62676B1 (sr) | 2012-09-11 | 2021-12-31 | Medivation Prostate Therapeutics Llc | Formulacije enzalutamida |
| EA202190820A1 (ru) | 2012-09-26 | 2021-10-29 | Арагон Фармасьютикалз, Инк. | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
| US9926399B2 (en) | 2012-11-21 | 2018-03-27 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EP3186247B1 (en) * | 2014-08-26 | 2021-03-03 | Astar Biotech LLC | Protein kinase inhibitors |
| MA41107A (fr) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
| SI3226843T1 (sl) | 2014-12-05 | 2021-11-30 | Aragon Pharmaceuticals, Inc. | Protirakavi sestavki |
| LT3226842T (lt) | 2014-12-05 | 2021-03-25 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| WO2016100905A1 (en) | 2014-12-19 | 2016-06-23 | Lutron Electronics Co., Inc. | Multi-channel lighting fixture having multiple light-emitting diode drivers |
| CN109219437A (zh) | 2016-06-03 | 2019-01-15 | 阿拉贡药品公司 | 抗癌组合物 |
| EP3555061B1 (en) | 2016-12-13 | 2023-06-07 | Watson Laboratories Inc. | Solid state forms of apalutamide |
| EP3592786B1 (en) | 2017-03-07 | 2023-05-10 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
| US10835638B2 (en) | 2017-08-17 | 2020-11-17 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
| WO2019078920A1 (en) | 2017-10-16 | 2019-04-25 | Aragon Pharmaceuticals, Inc. | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER |
| WO2019135254A1 (en) | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Apalutamide polymorphs and their preparation thereof |
| EP3740253B1 (en) | 2018-01-17 | 2023-08-16 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
| US20200270226A1 (en) * | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
| WO2020049598A2 (en) | 2018-09-08 | 2020-03-12 | Cipla Limited | Apalutamide polymorphs |
| IT201900003839A1 (it) | 2019-03-15 | 2020-09-15 | Olon Spa | Sintesi di apalutamide amorfa stabile |
| WO2020234817A1 (en) * | 2019-05-21 | 2020-11-26 | Laurus Labs Limited | Polymorphic forms of apalutamide and its preparation thereof |
| IT201900010593A1 (it) | 2019-07-01 | 2021-01-01 | Dipharma Francis Srl | Forma cristallina di un inibitore di recettori degli androgeni |
| WO2021033098A1 (en) * | 2019-08-22 | 2021-02-25 | Dr. Reddy’S Laboratories Limited | Process for the preparation of apalutamide |
| IT201900015974A1 (it) | 2019-09-10 | 2021-03-10 | Olon Spa | Apalutamide cristallina stabile in forma pura e processo per la sua preparazione |
| CN110590740A (zh) * | 2019-09-20 | 2019-12-20 | 武汉大学 | 一种阿帕鲁胺化合物及其药物制剂 |
| US20230312507A1 (en) | 2020-09-04 | 2023-10-05 | Synthon B.V. | Improved process for preparation of apalutamide |
| WO2023143090A1 (zh) * | 2022-01-25 | 2023-08-03 | 成都苑东生物制药股份有限公司 | 一种阿帕他胺溶剂化物新晶型及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| CN101032483B (zh) | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| DK2656842T3 (en) * | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| SG10201408699TA (en) * | 2006-03-29 | 2015-02-27 | Univ California | Diarylthiohydantoin compounds |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| MX355915B (es) * | 2010-02-16 | 2018-05-04 | Aragon Pharmaceuticals Inc | Moduladores del receptor de androgenos y usos de los mismos. |
| EP2858985B1 (en) | 2012-06-07 | 2018-04-18 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US20200270226A1 (en) | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
-
2013
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en active Application Filing
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active IP Right Grant
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active IP Right Grant
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en active Active
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
-
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
-
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
- 2015-11-11 HK HK15111086.5A patent/HK1210175A1/xx unknown
-
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389A patent/HK1226066A1/zh unknown
-
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
-
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-06-11 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
-
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-06-24 IL IL267608A patent/IL267608A/en unknown
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
-
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
-
2021
- 2021-01-26 US US17/158,806 patent/US20210163441A1/en active Pending
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-03 LT LTPA2021525C patent/LTPA2021525I1/lt unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140549A (es) | Formas cristalinas de un modulador del receptor androgénico | |
| HK1245764A1 (zh) | 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物 | |
| HK1245726A1 (zh) | 具有用於製造眼科鏡片的特徵結構的鏡片坯件 | |
| PH12016500968B1 (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| ZA201508207B (en) | Phakic lens device with openings and concentric annular zones | |
| CL2015002616A1 (es) | 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina. | |
| EP3039015A4 (en) | Substituted pyrimidine bmi-1 inhibitors | |
| IL243092B (en) | New triazolo[d–4,5]pyrimidine histories | |
| UY34778A (es) | ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?. | |
| EP3075218A4 (en) | INTEGRATION OF A MICRO-INVERTER TO A PHOTOVOLTAIC MODULE | |
| MX2018014178A (es) | Anticuerpo anti-fgfr2. | |
| EP3027619A4 (en) | Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors | |
| IN2015KN00365A (es) | ||
| IL231337A (en) | Optical receiver and transmitter - receiver that uses it | |
| EP3022157A4 (en) | Stable salt-free polyaluminum chlorosulfates | |
| EP3047619A4 (en) | Wake-up receiver with automatic interference rejection | |
| GB2530988B (en) | Monolithically integrated thin-film electronic conversion unit for lateral multifunction thin-film solar cells | |
| ZA201602232B (en) | Spectrophotometer for the characterisation of receivers of solar collectors | |
| GB2519659B (en) | Drinks Carrier With Deformable Support Holes | |
| EP3082846A4 (en) | Isoform of the tgf-beta receptor ii | |
| HK1221279A1 (zh) | 聚焦式中央太陽能接收器 | |
| CA2854747A1 (en) | Trousers with integrated bowl | |
| IN2012CH02984A (es) | ||
| MX2017006679A (es) | Formas cristalinas de inhibidores de poli adp-ribosa polimerasa (parp). | |
| UA59798U (ru) | Применение сиропа амкесола как вещества с бронхолитической активностью |